ArticleJournal of oral biology and craniofacial research
SFXN1 expression analysis in oral squamous cell carcinoma and its association with the PI3K-AKT-mTOR pathway and immune cell infiltration.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral squamous cell carcinoma (OSCC) is a predominant malignancy characterized by aggressive progression and poor prognosis. This study investigated the role of SFXN1 (Sideroflexin 1), a mitochondrial serine transporter, in OSCC using integrated bioinformatic and experimental approaches. Objective: To analyze the expression, clinical relevance, and functional associations of SFXN1 in OSCC through comprehensive bioinformatic and in vitro investigations. Methods: Transcriptomic data from TCGA pan-cancer cohorts were analyzed to evaluate SFXN1 expression patterns. The expression levels in OSCC were validated using KB OC cell lines, with clinical correlations assessed for tumor grade, nodal status, and patient survival. Immune infiltration associations and protein‒protein interaction networks were constructed, followed by pathway enrichment analyses. Experimental validation was performed via in vitro assays. Results: The results revealed that SFXN1 was significantly overexpressed in head and neck squamous cell carcinoma and markedly upregulated in KB cells compared with controls. SFXN1 expression was associated with tumor grade and nodal metastasis, although no significant stage-specific differences were observed. Survival analysis revealed no statistically significant association with overall survival. Immune infiltration analysis indicated modest but significant correlations between SFXN1 and immune cell populations, particularly CD4 Conclusion: These findings highlight the involvement of SFXN1 in cancer-related pathways and its potential role in OSCC, suggesting potential therapeutic targeting opportunities that need further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.